Oral drugs in the treatment of metastatic colorectal cancer

Pilar García-Alfonso, Andrés Jesús Muñoz Martín, Laura Ortega Morán, Javier Soto Alsar, Gabriela Torres Pérez-Solero, Montserrat Blanco Codesido, Pilar Aitana Calvo Ferrandiz and Silvina Grasso Cicala

Abstract: Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36 million new cases and almost 700,000 deaths annually. Approximately 21% of patients with CRC have metastatic disease at diagnosis. The objective of this article is to review the literature on the efficacy and safety of oral drugs available for the treatment of metastatic colorectal cancer (mCRC). Several such drugs have been developed, and fluoropyrimidines are the backbone of chemotherapy in this indication. They exert their antitumour activity by disrupting the synthesis and function of DNA and RNA. Oral fluoropyrimidines include prodrugs capecitabine, tegafur, eniluracil/5-fluorouracil, tegafur/uracil, tegafur/gimeracil/oteracil and trifluridine/tipiracil (FTD/TPI). Oral drugs offer several advantages over injectable formulations, including convenience, flexibility, avoidance of injection-related adverse events (AEs) and, in some circumstances, lower costs. However, oral drugs may not be suitable for patients with gastrointestinal obstruction or malabsorption, they may result in reduced treatment adherence and should not be co-administered with drugs that interfere with absorption or hepatic metabolism. Oral fluoropyrimidines such as capecitabine, as monotherapy or in combination with oxaliplatin, irinotecan or bevacizumab, are as effective as intravenous 5-fluorouracil (5-FU) in first-line treatment of mCRC. Other oral fluoropyrimidines, such as FTD/TPI, are effective in patients with mCRC who are refractory, intolerant or ineligible for 5-FU. In addition, oral fluoropyrimidines are used in adjuvant treatment of mCRC. Regorafenib is an oral multikinase inhibitor used in patients in whom several previous lines of therapy have failed. Frequent AEs associated with oral drugs used in the treatment of CRC include hand-foot syndrome and gastrointestinal and haematological toxicities.

Keywords: adjuvant, capecitabine, colorectal cancer, first-line, metastatic, S-1, TAS-102, UFT

Metastatic colorectal cancer
Colorectal cancer (CRC) is the third most common form of cancer worldwide after lung and breast cancers.1 Approximately 1.9 million new cases of CRC and 935,000 deaths occurred worldwide in 2020.1 At diagnosis, 21% of patients with CRC have metastatic disease.2

Risk factors for CRC can be divided into modifiable and non-modifiable.3,4 Modifiable risk factors include smoking and alcohol consumption, sedentary lifestyle with high meat consumption, high-fat and low-fibre diet, very low salt intake and low calcium and selenium intake.3-5 Non-modifiable risk factors include age, personal/family history and genetic predisposition.3,4

Treatment options for metastatic colorectal cancer (mCRC) include surgery, ablation, embolisation, radiotherapy and systemic therapy.6 Systemic therapy options, in turn, include chemotherapy with fluoropyrimidines, alone or in combination with oxaliplatin or irinotecan, and biological therapy targeting vascular endothelial...
growth factor (VEGF), epidermal growth factor receptor (EGFR) or multiple receptor tyrosine kinases, as in the case of regorafenib (Figure 1).7

Oral drugs offer a number of potential advantages over intravenous (IV) drugs, including improved convenience and lower costs.8–12 These are particularly important in patients with mCRC, who are often prescribed complex therapeutic regimens. Several oral drugs are now available for systemic treatment of mCRC, including capecitabine, tegafur/gimeracil/oteracil (S-1), trifluridine/tipiracil (FTD/TPI, formerly TAS-102) and regorafenib.

Fluoropyrimidines are the mainstay of chemotherotherapy in mCRC.13 The original member of this class, 5-fluorouracil (5-FU), was first synthesised in the 1950s.14 Since then, several other fluoropyrimidines have been approved, resulting in a notable improvement in prognosis in patients with CRC.13,15 More recently, the multiple kinase inhibitor regorafenib was approved for the treatment of mCRC: in 2012 in the USA and in 2013 in Europe.16,17 Another recent addition to this group is FTD/TPI, which was approved in the USA in 2015 and in Europe in 2016.18,19

This article reviews the literature on the efficacy and safety of oral drugs available for the treatment of mCRC.

**Oral fluoropyrimidines**

Oral fluoropyrimidine-based medicines can be broadly divided into two groups: (a) 5-FU prodrugs; and (b) combinations of 5-FU (or a 5-FU prodrug) with a dihydropyrimidine dehydrogenase (DPD) inhibitor. Prodrugs of 5-FU, such as capecitabine and tegafur, are characterised by the addition of a pyrimidine ring with a fluorine atom at position 5. As a result, they have much higher oral bioavailability and more predictable pharmacokinetics than 5-FU.20

**5-Fluorouracil (5-FU)**

5-FU is a pyrimidine analogue that acts as an antimetabolite of uracil, causing cell death. After entering the cell, 5-FU is converted to one of several active metabolites. These metabolites, in turn, inhibit the enzymes thymidylate synthase and uracil-DNA-glycosylase, interfering with DNA synthesis and repair, respectively. In addition, one of the 5-FU metabolites is incorporated into RNA, thereby disrupting its processing and function.21,22

Bioavailability of unmodified 5-FU after oral administration varies widely (0–80%) between patients and in the same patient. This variation is due primarily to differences in the activity of DPD, the enzyme responsible for its degradation. As a result, the efficacy and toxicity of oral 5-FU have been described as unpredictable and erratic. Therefore, the oral route of administration is seldom used for 5-FU.21,23,24

**Capecitabine**

The development of oral capecitabine was prompted by the need for improved tolerability and convenience compared with intravenous 5-FU regimens.8

Capecitabine is a fluoropyrimidine carbamate with an oral bioavailability approaching 100%. It is a prodrug of 5-FU, which is its only active metabolite. Following absorption in the intestine, capecitabine is converted to 5-FU in three metabolic steps, the last of which is catalysed by thymidine phosphorylase.25 This enzyme is found in higher concentrations in solid tumours than in surrounding tissues, which means that capecitabine produces fewer systemic adverse events than an IV formulation of 5-FU.25–27

Both in the USA and in Europe, capecitabine is approved for first-line monotherapy of mCRC.
and for adjuvant treatment of stage III (Dukes’ stage C) colon cancer.\textsuperscript{27,28}

**Capecitabine monotherapy.** Capecitabine was compared with bolus IV 5-FU/leucovorin (LV) in first-line treatment of patients with mCRC in two identically designed open-label phase III studies (Table 1).\textsuperscript{29,30} In a prospectively planned integrated analysis of these studies, capecitabine was associated with a significantly higher overall response rate than 5-FU/LV (26\% versus 17\%; \(p<0.0002\)). Median time to response and duration of response were similar. In addition, there were no significant differences in time to disease progression (TTP) or overall survival (OS) with capecitabine and 5-FU/LV (TTP: 4.6 months versus 4.7 months, \(p=0.95\); OS: 12.9 months versus 12.8 months, \(p=0.48\)).\textsuperscript{31}

In patients with mCRC, first-line capecitabine monotherapy demonstrated a more favourable safety profile than bolus IV 5-FU/LV.\textsuperscript{39} The incidence of diarrhoea, stomatitis, nausea, alopecia and grade 3 or 4 neutropenia was significantly lower with capecitabine than with 5-FU/LV (\(p<0.001\) for all). However, capecitabine was also associated with a significantly higher incidence of hand-foot syndrome than 5-FU/LV (\(p<0.001\)). Compared with those who received 5-FU/LV, patients treated with capecitabine required significantly fewer dose reductions (33.9\% versus 42.2\%, \(p=0.0037\)) and hospitalisations due to adverse events (11.6\% versus 18.0\%, \(p<0.005\)).\textsuperscript{39} The safety profile of capecitabine was similar in elderly patients with advanced CRC.\textsuperscript{40}

Capecitabine monotherapy has been associated with cardiovascular adverse events, including cardiac arrhythmias, angina pectoris, myocardial infarction, heart failure and cardiomyopathy, in 3–9\% of patients with CRC.\textsuperscript{27,41} Most of these patients had a history of cardiovascular dysfunction and caution is recommended in this population.\textsuperscript{27,28} The incidence of cardiovascular adverse events associated with capecitabine is similar to that observed with IV 5-FU.\textsuperscript{42–44}

**Capecitabine in combination with chemotherapy.** In patients with mCRC, capecitabine has been used as part of combination regimens with several drugs, including oxaliplatin, irinotecan, bevacizumab and cetuximab. In a meta-analysis of eight randomised controlled trials comparing capecitabine plus oxaliplatin (CAPOX or XELOX) and 5-FU plus LV plus oxaliplatin (FOLFOX) in the first-line treatment of patients with mCRC, there were no statistically significant differences between the two treatment regimens in terms of overall response rate, progression-free survival (PFS) or OS. However, the incidence of thrombocytopenia (\(p=0.0005\)), hand-foot syndrome (\(p<0.00001\)) and diarrhoea (\(p<0.00001\)) was significantly higher with XELOX compared with FOLFOX, while FOLFOX was more commonly associated with neutropenia than XELOX (\(p<0.00001\)).\textsuperscript{45}

Capecitabine plus irinotecan (XELIRI) as first-line chemotherapy demonstrated promising efficacy and safety results in a phase II, single-arm study of patients with mCRC.\textsuperscript{46}

In a meta-analysis of six randomised controlled trials that compared XELIRI with 5-FU/LV plus irinotecan (FOLFIRI) in first-line treatment of patients with mCRC, there were no significant differences in overall response rate, PFS or OS between the two regimens.\textsuperscript{47}

**Capecitabine in combination with biological drugs.** Capecitabine has also been combined with biological drugs bevacizumab and cetuximab. Capecitabine plus bevacizumab combination was evaluated in first-line treatment of elderly patients with mCRC in two phase II\textsuperscript{48,49} and one phase III trial.\textsuperscript{50} In the phase II trials, capecitabine plus bevacizumab combination was associated with an overall response rate of 34–65\%, a median PFS of 10.8–11.5 months and OS of 18.0–21.2 months.\textsuperscript{48,49} Capecitabine plus bevacizumab combination was compared with capecitabine alone in the phase III, randomised, open-label study in patients aged \(\geq 70\) years.\textsuperscript{50} Median PFS was significantly longer with capecitabine plus bevacizumab than with capecitabine alone (9.1 months versus 5.1 months, \(p<0.0001\)). Overall response rate was also significantly higher with capecitabine plus bevacizumab than with capecitabine alone (19\% versus 10\%, \(p=0.04\)). No significant differences were detected in OS (20.7 months versus 16.8 months, \(p=0.18\)).\textsuperscript{50} Commonly reported grade 3 or 4 treatment-related adverse events in this population include hand-foot syndrome, diarrhoea and deep vein thrombosis.\textsuperscript{48–50}
Table 1. Key clinical trials of oral fluoropyrimidines.

| Author [reference] | Study design | Treatment (n) | ORR, % | PFS, months | TTP, months | OS, months | Safety |
|--------------------|--------------|---------------|--------|-------------|-------------|------------|--------|
| **Capecitabine**   |              |               |        |             |             |            |        |
| Hoff et al.29      | MC, OL, R, phase III | CAPE 1250 mg/m² PO BID d1–14 q3w [302] | 24.8 \( p = 0.005 \) versus LEU + 5-FU | NR | 4.3 | 12.5 | CAPE: ↓ diarrhea, stomatitis, nausea, alopecia \( p < 0.0002 \) versus LEU + 5-FU; ↓ G3/4 stomatitis, neutropenia \( p < 0.001 \); ↑ G3 hand-foot syndrome \( p < 0.00001 \), G3/4 hyperbilirubinemia |
|                    |              | LEU 20 mg/m² IV then IV 5-FU 425 mg/m² OD d1–5 q4w [303] | 15.5 | NR | 4.7 | 13.3 |        |
| Van Cutsem et al.30 | MC, OL, R, phase III | CAPE 1250 mg/m² PO BID d1–14 q3w [301] | 18.9 | NR | 5.2 | 13.2 | CAPE: ↓ stomatitis, alopecia \( p < 0.00001 \); ↑ hand-foot syndrome \( p < 0.00001 \); ↑ G3/4 stomatitis, neutropenia \( p < 0.00001 \); ↑ G3 hand-foot syndrome \( p < 0.00001 \), uncomplicated G3/4 hyperbilirubinemia |
|                    |              | LEU 20 mg/m² IV then IV 5-FU 425 mg/m² OD d1–5 q4w [301] | 15.0 | NR | 4.7 | 2.1 |        |
| **Eniluracil/5-FU** |              |               |        |             |             |            |        |
| Schilsky et al.32  | MC, R, OL, phase III | Eniluracil 11.5 mg/m² PO BID d1–28 q5w + 5-FU 1.15 mg/m² PO BID d1–28 q5w [485] | NR | 20.0 | NR | 13.3 | Eniluracil/5-FU: ↓ grade 3 or 4 granulocytopenia |
|                    |              | LEU 20 mg/m² IV then IV 5-FU 425 mg/m² OD d1–5 q4w [479] | NR | 22.7 \( p = 0.01 \) versus eniluracil/5-FU | NR | 14.5 |        |
| **S-1**            |              |               |        |             |             |            |        |
| Kwakman et al.31   | MC, R, OL, phase III | CAPE 1250 mg/m² for patients <70 years old or 1000 mg/m² for patients ≥70 years old PO BID d1–14 + BEV 7.5 mg/kg IV d1 q3w [80] | 17 \( p = 0.09 \) versus S-1 | 8.2 \( p = 0.93 \) versus S-1 | NR | NR | CAPE: ↑ any grade hand-foot syndrome \( p < 0.0005 \), grade 3 hand-foot syndrome \( p = 0.003 \) S-1: ↑ grade 3 anorexia \( p = 0.03 \). |
|                    |              | S-1 30 mg/m² PO BID d1–14 + BEV 7.5 mg/kg IV d1 q3w [80] | 32 | 8.4 | NR | NR |        |
| Hong et al.34      | MC, R, OL, phase III | S-1 40 mg/m² PO BID d1–14 + OXA 130 mg/m² IV d1 q3w [168] CAPE 1250 mg/m²/PO BID d1–14 + OXA 130 mg/m² IV d1 q3w [CAPOX, 172] | 47 \( p = 0.029 \) versus CAPOX | 8.5 \( p = 0.93 \) versus CAPOX | NR | 21.2 \( p = 0.18 \) versus CAPOX | 20.5 | SOX: ↑ grade 3–4 neutropenia, thrombocytopenia, diarrhoea CAPOX: ↑ any grade hand-foot syndrome |
|                    |              | CAPE 1250 mg/m² PO BID d1–14 + OXA 130 mg/m² IV d1 q3w [168] | 36 | 6.7 | NR |        |        |
| Yasui et al.35     | MC, R, OL, phase III | IRI 125 mg/m² IV d1, 15 + S-1 40–60 mg/m² PO BID d1–14 q4w [IRIS; 213] LEU 20 mg/m² IV d1 + IRI 150 mg/m² IV d1 + 5-FU 400 mg/m² IV d1 then 5-FU 2400 mg/m² IV d1–2 q4w [FOLFIRI; 213] | NR | 5.8 | NR | 17.8 | IRIS: ↑ grade 3 diarrhoea |
|                    |              | IRI 125 mg/m² IV d1, 15 + S-1 40–60 mg/m² PO BID d1–14 q4w [IRIS; 213] LEU 20 mg/m² IV d1 + IRI 150 mg/m² IV d1 + 5-FU 400 mg/m² IV d1 then 5-FU 2400 mg/m² IV d1–2 q4w [FOLFIRI; 213] | NR | 5.1 | NR | 17.4 | FOLFIRI: ↑ grade 3 or 4 neutropenia |

(Continued)
### Table 1. (Continued)

| Author (reference) | Study design | Treatment (n) | ORR, % | PFS, months | TTP, months | OS, months | Safety |
|--------------------|--------------|---------------|--------|-------------|-------------|------------|--------|
| **Trifluridine/tipiracil** | | | | | | | |
| Mayer et al. | MC, R, DB, phase III | FTD/TPI 35mg/m² BID d1–5, 8–14 q4w + BSC [534] PBO + BSC [266] | NR | 2.0 [p < 0.001 versus PBO] 1.7 | NR | 7.1 [p < 0.001 versus PBO] 5.3 | FTD/TPI: neutropenia 38%, leukopenia 21% PBO: neutropenia <1%, leukopenia 5% |
| **Regorafenib** | | | | | | | |
| Grothey et al. | MC, R, DB, phase III | REG 160 mg OD d1–21 q4w + BSC [505] PBO + BSC [255] | NR | 1.9 [p < 0.0001 versus PBO] 1.7 | NR | 6.4 [p = 0.0052 versus PBO] 5.0 | REG: ↑grade 3 or 4 hand-foot syndrome, fatigue, diarrhoea, hypertension, rash or desquamation |
| Li et al. | MC, R, DB, phase III | REG 160 mg OD d1–21 q4w + BSC [136] PBO + BSC [68] | NR | 3.2 [p < 0.0001 versus PBO] 1.7 | NR | 8.8 [p = 0.00016 versus PBO] 6.3 | REG: ↑grade 3 or 4 hand-foot syndrome, hypertension, hyperbilirubinaemia, hypophosphataemia, ALT increased, AST increased, lipase increased, maculopapular rash |

5-FU, 5-fluorouracil; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BEV, bevacizumab; BID, twice daily; BSC, best standard of care; CAPE, capecitabine; d, day; DB, double blind; FTD, trifluridine; G, grade; IRI, irinotecan; IV, intravenous; IRI, irinotecan; LEU, leucovorin; MC, multicentre; NR, not reported; OD, once daily; OL, open label; ORR, overall response rate; OS, overall survival; OXA, oxaliplatin; PBO, placebo; PFS, progression-free survival; PO, oral; q4w, every 4 weeks; R, randomised; REG, regorafenib; S-1, tegafur plus gimeracil plus oteracil; TPI, tipiracil; TTP, time to progression; UFT, uracil plus fltorafur (tegafur).
Several studies have examined the efficacy of capecitabine plus irinotecan (CAPIRI) plus bevacizumab as first-line treatment of patients with mCRC. The addition of bevacizumab improved PFS, but not OS. CAPIRI plus bevacizumab had an acceptable tolerability profile.

First-line capecitabine plus cetuximab was evaluated in elderly patients (70 years or older) with advanced CRC in a phase II trial. In patients with wild-type KRAS, capecitabine plus cetuximab combination was associated with a response rate of 48.3% and a median PFS of 8.4 months. However, the high incidence of paronychia and grade 3 or 4 acne-like rash necessitated dose reductions in 27.3% of patients. This reduced the incidence of paronychia, but not of acne-like rash.

The phase III COIN study investigated the efficacy of first-line CAPOX or FOLFOX versus CAPOX or FOLFOX plus cetuximab and found no difference in terms of OS or PFS. A subanalysis of this study compared CAPOX plus cetuximab with FOLFOX plus cetuximab and showed a longer PFS for FOLFOX plus cetuximab and worse tolerance with CAPOX plus cetuximab, with significantly higher incidences of diarrhoea and hand-foot syndrome. For these reasons, the use of anti-EGFR antibodies with capecitabine-based chemotherapy is not recommended.

Eniluracil/5-FU
Eniluracil (5-ethynyluracil) is a potent and irreversible inhibitor of DPD, the primary rate-limiting enzyme responsible for catabolism of 5-FU. Eniluracil does not appear to have any inherent toxicity and most of the administered dose is excreted in urine unchanged. In patients with mCRC, eniluracil has been shown to reduce DPD activity in the primary tumour, metastases and normal tissues to undetectable levels. Co-administration with eniluracil results in complete oral bioavailability of 5-FU, increasing its half-life from about 20 minutes to up to 6.5 hours and makes its pharmacokinetics linear and predictable.

In a multicentre phase III study, oral eniluracil plus 5-FU showed decreased efficacy compared with standard 5-FU/LV regimen as first-line therapy in patients with mCRC. Median OS was 13.3 months with eniluracil plus 5-FU versus 14.5 months with 5-FU/LV, and PFS was 20 weeks versus 22.7 weeks, respectively. It was hypothesised that in this study, excess eniluracil could have been diminishing 5-FU efficacy by competing for enzymes that convert 5-FU to its active metabolites, and that by reducing the dose and schedule of eniluracil, higher efficacy could be achieved in future trials. The outcome of this phase III trial was unexpected because preclinical and early clinical data were considered to be encouraging. At present, eniluracil is not approved for the treatment of mCRC.

Tegafur and tegafur/uracil (UFT)
Tegafur (florafur) is a furanyl nucleoside analogue and a prodrug of 5-FU. Oral tegafur is absorbed in the gastrointestinal (GI) tract and metabolised to 5-FU primarily by cytochrome P450 enzymes in the liver and, to a lesser extent, by soluble enzymes in tumour tissue, which leads to a gradual, but sustained level of 5-FU in tumours. Tegafur has a plasma half-life of 5–12 h.

In phase I and II studies, tegafur demonstrated efficacy similar to that of IV 5-FU and was associated with fewer haematological adverse events than 5-FU. However, tegafur was also characterised by severe GI and central nervous system (CNS) toxicity (depression, headache, lethargy, dizziness) which has limited its use.

UFT is an oral, fixed-dose combination of tegafur and uracil (1:4), developed in an attempt to improve the efficacy of tegafur. Uracil acts as a competitive substrate of DPD, thereby reducing the inactivation of 5-FU. This allows for lower doses of tegafur to be administered, which, in turn, decreases neurotoxicity.

Several studies evaluated UFT in combination with leucovorin in patients with mCRC. A multicentre phase III study compared oral UFT plus leucovorin (UFT 300 mg/m²/day and leucovorin 75 or 90 mg/day, both for 28 consecutive days of 35-day cycles) with IV bolus 5-FU plus LV (5-FU 425 mg/m²/day and LV 20 mg/m²/day, both for five consecutive days of 28-day cycles) in previously untreated patients with mCRC. This study showed equivalence in OS with UFT plus LV (12.4 months) versus 5-FU/LV (13.4 months, \( p = 0.630 \)). There was also no difference in the overall response rate between the two treatments (11.7% versus 14.5%, \( p = 0.232 \)). The incidence of several adverse events was lower in the UFT
plus LV group compared with the IV 5-FU/LV group, including diarrhoea, nausea, vomiting, stomatitis, mucositis, neutropenia and documented infections. The authors concluded that UFT plus LV was an equally effective, but safer and more convenient alternative to IV 5-FU/LV.69 Another phase III study compared the efficacy of UFT plus LV versus IV 5-FU/LV in previously untreated patients with mCRC, but no statistically significant difference in time to progression was observed between treatments.70 UFT was also effective in heavily pre-treated patients with mCRC.71

UFT has been studied in several other combinations, including UFT plus LV plus oxaliplatin (TEGAFOX), UFT plus LV plus irinotecan (TEGAFIRI) and TEGAFIRI plus cetuximab. In patients with mCRC, these combinations showed efficacy similar to equivalent IV 5-FU combinations.72,73

Depending on the administration schedule, myelosuppression or diarrhoea were the dose-limiting toxicities of UFT in phase I studies.20 Compared with 5-FU, UFT has a more favourable safety profile.73 Unlike other fluoropyrimidines, UFT rarely causes hand-foot syndrome. UFT has been shown to be a safe alternative to 5-FU in patients with partial DPD deficiency.74

UFT is approved for the treatment of mCRC in 60 countries, including Japan and the Philippines.75,76 UFT is approved in combination with LV for first-line therapy of mCRC in 12 European countries, including France and the UK.76

Tegafur/gimeracil/oteracil (S-1). S-1 is a combination of tegafur and two 5-FU modulators, gimeracil (5-chloro-2,4-dihydroxypyridine; CDHP) and oteracil or oxonic acid, at the molar ratio of 1:0.4:1.77,78 Gimeracil is a reversible inhibitor of DPD that is 200 times more potent than uracil.77 Its addition increases the serum half-life of tegafur and its concentration in tumour tissues. GI toxicity commonly associated with fluoropyrimidines results from phosphorylation of 5-FU by orotate phosphoribosyl transferase. Oteracil inhibits this enzyme, decreasing 5-FU phosphorylation in the GI tract and thereby reducing the GI toxicity of tegafur.77

Most phase III studies of S-1 in mCRC have been conducted in Asian patients (Table 1). In a phase III study conducted by Hong et al.,34 S-1 plus oxaliplatin (SOX) as first-line treatment for mCRC was non-inferior to CAPOX with regard to PFS. As a result, the authors concluded that SOX could be an alternative to CAPOX as first-line chemotherapy for patients with mCRC.34 In another phase III study conducted in Asian patients with mCRC, first-line treatment with SOX plus bevacizumab was shown to be non-inferior to FOLFOX plus bevacizumab.79 The results of this study lead to an update of the Asian guidelines for first-line treatment of mCRC, with SOX plus bevacizumab becoming the first choice.80

In second-line treatment of mCRC, S-1 plus irinotecan (IRIS) and FOLFIRI were associated with similar PFS and OS in Asian patients.81 The median PFS in patients treated with IRIS was 5.8 months compared with 5.1 months in the FOLFIRI group.81 In an updated report on this study, OS was higher in patients treated with IRIS than in patients treated with FOLFIRI.35 These results show that IRIS may be an alternative option to FOLFIRI in Asian patients.

The randomised phase III TRICOLORE study conducted in Japan demonstrated that IRIS plus bevacizumab was non-inferior to FOLFOX or CAPOX plus bevacizumab with respect to PFS as first-line treatment of mCRC, and could be a new standard treatment in this indication.82

To our knowledge, the only phase III study conducted in western patients, the SALTO study, evaluated S-1 monotherapy versus capecitabine in the first-line treatment of mCRC.33 Relative to capecitabine, S-1 produced similar efficacy outcomes including response rate, PFS and OS.33

S-1 was first approved in Japan in 1999 for the treatment of gastric cancer and was subsequently approved in Japan for six additional indications including CRC.83 In Europe, S-1 was authorised in March 2011 for the treatment of advanced gastric cancer in combination with cisplatin.84

**DPD deficiency**

DPD is the first enzyme in the 5-FU catabolism pathway, and is responsible for the elimination of over 80% of systemic 5-FU.85 Due to mutations in the DPYD gene, approximately 3–5% of the general population have partial DPD deficiency, and 0.2% have complete DPD deficiency.74
The use of 5-FU and 5-FU prodrugs is associated with severe and life-threatening adverse events in patients with DPD deficiency, including stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity. As a result, the European Medicines Agency (EMA) recommends that patients should be tested for DPD activity before receiving 5-FU, capecitabine or tegafur. Patients with complete DPD deficiency should not receive any of these drugs. In patients with partial DPD deficiency, administration of reduced doses is permissible but should be accompanied by vigilant adverse event monitoring. In the USA, the prescribing information for capecitabine warns of an increased risk of severe or fatal adverse events in patients with DPD deficiency. It advises that treatment be withheld or stopped in patients receiving capecitabine who present with acute early-onset or unusually severe adverse effects, but does not explicitly recommend testing for DPD activity before starting treatment. Instead, patients should be counselled to notify their healthcare provider if they have a known DPD deficiency.

**Trifluridine/tipiracil (FTD/TPI)**

FTD is a nucleoside analogue and the active cytotoxic component of the FTD/TPI combination. FTD is a thymidylate synthase inhibitor, but a less potent one than 5-FU. On the other hand, FTD metabolites are much more readily incorporated into DNA than 5-FU metabolites, and this is believed to be the primary mechanism of FTD cytotoxicity. Importantly, the antineoplastic effect of FTD was retained in xenograft models resistant to 5-FU. However, the oral bioavailability of FTD is low due to extensive metabolism in the GI tract and liver by thymidine phosphorylase. Co-administration of FTD with a thymidine phosphorylase inhibitor (TPI) increases exposure to FTD 38-fold and peak plasma concentration 22-fold. The optimal molar ratio of FTD to TPI is 1:0.5, which is available as a fixed-dose combination. Preclinical studies suggest that FTD is not metabolised by DPD; therefore, it could be a useful alternative to 5-FU or its prodrugs in patients with DPD deficiency. However, before FTD can be recommended in this setting, studies in humans would need to confirm this information.

**FTD/TPI monotherapy**

FTD/TPI has been studied in the treatment of patients with mCRC who had two or more lines of previous therapy and were refractory, intolerant to or ineligible for 5-FU. In a phase II study in Japanese patients, FTD/TPI plus best supportive care was associated with significantly longer median PFS and OS than placebo plus best supportive care. In the randomised phase III TERRA study conducted in China, the Republic of Korea and Thailand, FTD/TPI was associated with significantly longer OS compared with placebo, while the incidence of serious adverse events was similar. In a phase III (RECURSE) international study, compared with placebo plus best standard of care, FTD/TPI plus best standard of care showed statistically significant improvements in median PFS (1.7 months versus 2.0 months; \( p < 0.001 \)) and OS (5.3 months versus 7.1 months; \( p < 0.001 \)) (Table 1). In a post-hoc analysis of RECURSE, low tumour burden and indolent disease were indicators of good prognosis in later-line treatment of patients with mCRC; patients with no liver metastases appeared to have the best prognosis, with a median OS of 16.4 months. Based on the phase III RECURSE study, the US Food and Drug Administration (FDA) approved FTD/TPI for the treatment of patients with mCRC who have previously been treated with fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, and, if RAS wild-type, an EGFR therapy. The EMA approved FTD/TPI for the treatment of adult patients with mCRC who have previously been treated with, or are not considered candidates for, available therapies including fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapies, anti-VEGF agents and anti-EGFR agents.

**FTD/TPI in combination with biological drugs**

FTD/TPI plus bevacizumab combination was evaluated in first-line treatment of patients with mCRC who are ineligible for intensive therapy in a phase II study (TASCO1). In the primary analysis, FTD/TPI plus bevacizumab was associated with longer PFS (9.2 months) than capecitabine plus bevacizumab [7.8 months; hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.48, 1.06]. An ongoing randomised phase III study (SOLSTICE) will compare FTD/TPI plus bevacizumab versus capecitabine plus bevacizumab in this indication (EudraCT2017-004059-22).

The combination of FTD/TPI with bevacizumab was also investigated in patients with refractory
In the phase I/II C-TASK FORCE study, FTD/TPI plus bevacizumab was associated with a 16-week PFS rate of 42.9%, suggesting that this combination could become a potential treatment option for patients with refractory mCRC.96 Another randomised, phase II study showed that the median OS was significantly longer in the FTD/TPI plus bevacizumab arm (10.3 months) than in the FTD/TPI alone arm (7.3 months; HR 0.42, 95% CI 0.18, 0.99, \( p < 0.05 \)). Median PFS was also significantly longer with combination therapy (5.9 months) than with FTD/TPI monotherapy (2.6 months; HR 0.51, 95% CI 0.28, 0.92, \( p < 0.03 \)).97 In addition, a phase Ib/II BiTS study, which evaluated the efficacy and safety of FTD/TPI plus bevacizumab in patients with mCRC who were refractory or intolerant to standard therapies, showed that at 16 weeks the PFS rate was 40.9%, the response rate was 0.0% and the disease control rate was 59.1%. The median PFS, median time to treatment failure and median OS were 4.2 months, 4.2 months and 8.7 months, respectively.98

**Safety.** Adverse events (of any grade) commonly associated with FTD/TPI include neutropenia, asthenia/fatigue, nausea, thrombocytopenia, decreased appetite, diarrhoea, vomiting, abdominal pain, pyrexia, leukopenia and anaemia.18,19,36 In the TASCO1 study, GI and haematological adverse events were more common in patients who received FTD/TPI plus bevacizumab combination than in patients who received capecitabine plus bevacizumab. Conversely, hand-foot syndrome was more common in the capecitabine plus bevacizumab group than in the FTD/TPI plus bevacizumab group (52.6% versus 3.9%).94 Strategies for the management of adverse events with FTD/TPI include dose reductions, withholding treatment and prophylactic administration of myeloid growth factors.99

**Regorafenib**

Regorafenib is a small-molecule multikinase inhibitor. Regorafenib is metabolised in the liver by cytochrome P450 3A4 and UDP-glucuronosyltransferase 1A9.100 Regorafenib has two main active metabolites, M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl). Regorafenib, M-2 and M-5 inhibit a number of kinases involved in oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E) and angiogenesis (vascular endothelial growth factor receptor (VEGFR)1, VEGFR2, VEGFR3, TIE2), as well as kinases involved in other processes (PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2).100,101

In 2012, regorafenib was approved in the USA for the treatment of patients with mCRC who have previously been treated with fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy and anti-VEGF therapy, as well as anti-EGFR therapy for patients with wild-type KRAS gene.16 In 2013, regorafenib was approved for the treatment of mCRC in Europe.17 The efficacy of regorafenib monotherapy in the management of previously treated patients with mCRC was evaluated in two randomised, placebo-controlled, phase III studies.37,38 In the international CORRECT study, regorafenib was associated with significantly longer OS (6.4 months versus 5.0 months, \( p = 0.0052 \)) and PFS (1.9 months versus 1.7 months, \( p < 0.0001 \)) compared with placebo.37 Similar results were observed in the CONCUR study that was conducted in Asian patients. Relative to placebo, OS (8.8 months versus 6.3 months, \( p = 0.00016 \)) and PFS (3.2 months versus 1.7 months, \( p < 0.0001 \)) were significantly longer with regorafenib.38

Treatment-related adverse events were reported in 93% and 97% of patients who received regorafenib in CORRECT and CONCUR, respectively.37,38 The most common serious adverse event in both studies was hand-foot syndrome (17% and 16%, respectively).37,38

**Oral versus IV drugs**

Patients prefer oral to IV palliative chemotherapy, provided that oral therapy is equally effective.8 This review shows that most oral drugs commonly used in the treatment of mCRC have similar efficacy compared to IV drugs. The only oral treatment that appears to be less effective is eniluracil plus oral 5-FU, as it was associated with inferior PFS and OS in patients with mCRC;32 this is why eniluracil is no longer being developed. Regarding safety, oral and IV drugs have shown different patterns of side effects and future research may help to determine the basis for these differences.102

Oral formulations have a number of advantages compared with IV formulations, including higher patient preference, avoiding infusions and the use of central catheters, fewer injection-associated adverse events and lower costs.8,10–12 A study
assessing patient preference for oral versus IV palliative chemotherapy has shown that patients with incurable cancer have a clear preference for oral chemotherapy, but are generally not willing to sacrifice efficacy for their preference. In this study, nine out of 10 patients with cancer preferred oral to IV chemotherapy. At the same time, two-thirds of patients were not prepared to accept reduced effectiveness.8 In a randomised crossover study, in which patients with advanced CRC received IV 5-FU or oral UFT for one cycle and then switched to the other treatment for the second cycle, 84% of patients preferred the oral UFT regimen because of convenience and less toxicity.9 Similarly, in another randomised crossover study, previously untreated patients with mCRC received oral UFT or bolus IV 5-FU for one cycle, switched to the other treatment for the second cycle and were then able to choose one of the regimens to continue their treatment until disease progression; 90% of patients chose UFT and only 10% chose 5-FU.10 Collectively, these results confirm that patients with CRC prefer oral therapy. Commonly cited reasons included convenience, flexibility and less disruption to normal daily activities.9,10,12 However, when the toxicity of an oral formulation is greater than the toxicity of an IV formulation, patients with CRC prefer the latter.103 In addition, IV anticancer therapy is associated with thromboembolic adverse events due to the use of venous catheters.104 Finally, orally administered fluoropyrimidines have been associated with lower costs of managing adverse events and less time lost due to treatment than IV 5-FU.11

At the same time, oral drugs have some disadvantages. For instance, they may not be suitable for patients with GI obstruction or malabsorption. In addition, treatment adherence may be reduced due to the fact that oral drugs are self-administered.13 Finally, care must be taken to avoid co-administration with drugs that can interfere with absorption or hepatic metabolism. Antacids, salicylates, antibiotics and anticonvulsants should be taken with caution. For example, acute phenytoin intoxication was observed in patients receiving tegafur or capcitabine, presumably because these drugs interfere with phenytoin metabolism.105,106

Regorafenib and FTD/TPI are recommended by the European guidelines for use in a third line setting in mCRC.7 Similar to capcitabine, regorafenib is commonly associated with hand-foot syndrome, while FTD/TPI often leads to haematological toxicities. While haematological toxicities are a concern, they tend to have less impact on the patient’s quality of life than more symptomatic adverse events such as hand-foot syndrome. Thus, differences between the safety and tolerability profiles of the two agents, and in particular the propensity of regorafenib to cause hand-foot syndrome and liver dysfunction, may explain why FTD/TPI appears to be associated with better treatment adherence compared with regorafenib.107 In a recent study, treatment adherence was approximately two to three times greater with FTD/TPI than with regorafenib; duration of treatment was also significantly longer with FTD/TPI than regorafenib.107,108

Conclusion

Therapies available for the treatment of mCRC include combinations of 5-FU or 5-FU prodrugs and DPD inhibitors (capcitabine, tegafur, eniluracil/5-FU, UFT, S-1), as well as a 5-FU analogue plus thymidine phosphorylase inhibitor combination (FTD/TPI) and a multikinase inhibitor (regorafenib). With the exception of eniluracil/5-FU, these oral therapies appear to be as effective as IV therapies, while also offering several advantages such as greater convenience and flexibility, avoidance of injection-related adverse effects.
events and, in some circumstances, lower costs. However, oral therapies are not suitable for patients with malabsorption and cannot be co-administered with drugs that affect hepatic metabolism. Unlike 5-FU and its prodrugs, FTD/TPI and regorafenib may have utility in patients with DPD deficiency; however, well-designed clinical trials are needed to confirm this. FTD/TPI and regorafenib appear to have similar efficacy, but treatment adherence and persistence are higher with FTD/TPI than with regorafenib. This may be because haematological adverse events that are commonly associated with FTD/TPI cause less disruption and distress to patients than the hand-foot syndrome commonly associated with regorafenib. Efficacy data from recent trials of oral and biological drug combinations, such as FTD/TPI with bevacizumab, have been encouraging, and demonstrate how such innovative regimens could continue to improve outcomes in the future. Clinical trials of regorafenib in combination with checkpoint inhibitors, such as nivolumab and pembrolizumab, are ongoing, and the results of these studies are eagerly awaited.

Acknowledgements
The authors would like to thank Nishad Parkar and Georgii Filatov of Springer Healthcare Communications for writing the outline and first draft of the manuscript, respectively.

Author contributions
Pilar García-Alfonso and Silvina Grasso Cicala contributed to the design of the manuscript and reviewed and approved all drafts.

Gabriela Torres Pérez-Solero, Laura Ortega Morán, Andrés Jesús Muñoz Martín,Montserrat Blanco Codesido, Pilar Aitana Calvo Ferrandiz and Javier Soto Alsar reviewed and approved all drafts of the manuscript.

Conflict of interest statement
The authors declare relevant conflicts of interest relating to: consultancy services or participation in advisory boards (*); speaking engagements (†); receipt of research funding (‡); support for attendance at congresses or other events (including travel and accommodation) (§); employment of self or a close family member (#); and participation in speaker bureaux (¶); for the following named commercial entities.

Pilar García-Alfonso: Amgen*†, Bayer*, Bristol-Myers Squibb*, Celgene*, Lilly*†, Merck*†, MSD*, Roche*†, Sanofi* and Servier*†.

Andrés Jesús Muñoz Martín: Bayer¶, Bristol-Myers Squibb*, Celgene*‡, Daiichi-Sankyo*, Eli Lilly*, Halozyme*, Leo Pharma*‡, MSD*, Pfizer*, Roche‡, Rovi‡, Sanofi‡ and Servier†. Dr Muñoz Martín also declares ownership of and receipt of royalties in relation to patents and other intellectual property in respect of a risk assessment model for venous thromboembolism in patients with cancer.

Laura Ortega Morán: Amgen‡§, Leo Pharma‡§, Roche§ and Sanofi*†‡

Javier Soto Alsar: Angelini§, MSD§, Pfizer§#, Rovi§, Roche§, Sanofi# and Vifor Pharma§

Gabriela Torres Pérez-Solero: Amgen†, Ipsen‡, Lilly‡, Merck‡†, Pfizer‡, Roche‡†, Servier†, Sanofi† and Advanced Accelerator Applications, a Novartis owned company*‡

Montserrat Blanco Codesido: Astellas‡, Beigene‡, Bristol-Myers Squibb‡, Ipsen‡†, Lilly‡‡§ and Roche§

Silvina Grasso Cicala: Servier#

Pilar Aitana Calvo Ferrandiz declares no conflicts of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The medical writing assistance was funded by Servier.

ORCID iD
Pilar García-Alfonso https://orcid.org/0000-0002-4373-9978

References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Epub ahead of print 4 February 2021. DOI: 10.3322/caac.21660

2. Noone A, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975–2015, based on November 2017 SEER data submission. https://seer.cancer.gov/statfacts/html/colorect.html (2017, accessed 27 August 2018).

3. Haggar FA and Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival,
and risk factors. Clin Colon Rectal Surg 2009; 22: 191–197.

4. Marley AR and Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet 2016; 7: 105.

5. Tárraga López PJ, Albero JS and Rodriguez-Montes JA. Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol 2014; 7: 33–46.

6. Carethers JM. Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap Adv Gastroenterol 2008; 1: 33–42.

7. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–1422.

8. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–115.

9. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5: 1696–1702.

10. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349–358.

11. Delaunoit T, Neczyporenko F, Hendiisz A, et al. Oral fluoropyrimidines in colorectal cancer: a door open to the future? Acta Gastroenterol Belg 2004; 67: 331–333.

12. Lima AP and del Giglio A. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl) 2005; 14: 151–154.

13. Kwakman J and Punt C. Oral drugs in the treatment of metastatic colorectal cancer. Expert Opin Pharmacother 2016; 17: 1351–1361.

14. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663–666.

15. Meyerhardt JA and Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476–487.

16. US Food and Drug Administration (FDA). Stivarga. New drug application approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203085Orig1s000ltr.pdf (2012, accessed 18 October 2018).

17. European Medicines Agencmu. Stivarga. EPAR summary for the public. https://www.ema.europa.eu/documents/overview/stivarga-epar-summary-public_en.pdf (2013, accessed 18 October 2018).

18. Taiho Oncology. Trifluridine and tipiracil (TAS-102). Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf (2015, accessed 20 February 2018).

19. Les Laboratoires Servier. TAS-102 (Lonsurf). Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003897/WC500206246.pdf (2016, accessed 20 February 2018).

20. Mulet-Martino M and Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7: 288–323.

21. Diasio RB and Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215–237.

22. Longley DB, Harkin DP and Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–338.

23. Diasio RB and Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994; 12: 2239–2242.

24. Eng C, Kindler HL and Schilsky RL. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer 2001; 1: 95–103.

25. Walko CM and Lindley C. Capecitabine: a review. Clin Ther 2005; 27: 23–44.

26. Di Costanzo F, Sdrobolini A and Gasperoni S. Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. Crit Rev Oncol Hematol 2000; 35: 101–108.

27. Roche Ltd. Capecitabine. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000316/WC500058151.pdf (2006, accessed 20 February 2018).

28. Genetech USA Inc. Capecitabine. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf (2015, accessed 20 February 2018).

29. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer:
results of a randomized phase III study. *J Clin Oncol* 2001; 19: 2282–2292.

30. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capcitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. *J Clin Oncol* 2001; 19: 4097–4106.

31. Van Cutsem E, Hoff PM, Harper P, et al. Oral capcitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. *Br J Cancer* 2004; 90: 1190–1197.

32. Schilsky RL, Levin J, West WH, et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. *J Clin Oncol* 2002; 20: 1519–1526.

33. Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase III trial of S-1 versus capcitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. *Ann Oncol* 2017; 28: 1288–1293.

34. Hong YS, Park YS, Lim HY, et al. S-1 plus oxaliplatin versus capcitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. *Lancet Oncol* 2012; 13: 1125–1132.

35. Yasui H, Muro K, Shimada Y, et al. A phase 3 non-inferiority study of 5-FU/L-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. *J Cancer Res Clin Oncol* 2015; 141: 153–160.

36. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med* 2015; 372: 1909–1919.

37. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013; 381: 303–312.

38. Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2015; 16: 619–629.

39. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capcitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. *Ann Oncol* 2002; 13: 566–575.

40. Feliu J, Escudero P, Llosa F, et al. Capcitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopath cooperative group study. *J Clin Oncol* 2005; 23: 3104–3111.

41. Kadoyama K, Miki I, Tamura T, et al. Adverse event profiles of 5-fluorouracil and capcitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. *Int J Med Sci* 2012; 9: 33–39.

42. Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capcitabine is typical of that reported with 5-fluorouracil. *Ann Oncol* 2002; 13: 484–485.

43. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. *J Cancer Res Clin Oncol* 2008; 134: 75–82.

44. Kwakman JJ, Simkens LH, Mol L, et al. Incidence of capcitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. *Eur J Cancer* 2017; 76: 93–99.

45. Guo Y, Xiong BH, Zhang T, et al. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. *Cancer Invest* 2016; 34: 94–104.

46. García-Alfonso P, Muñoz-Martín A, Mendez-Urena M, et al. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI Group. *Br J Cancer* 2009; 101: 1039–1043.

47. Guo Y, Shi M, Shen X, et al. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis. *Clin Colorectal Cancer* 2014; 13: 110–118.

48. Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. *Br J Cancer* 2010; 102: 1468–1473.

49. Vrdoljak E, Omrcen T, Boban M, et al. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly...
patients with metastatic colorectal cancer. *Anticancer Drugs* 2011; 22: 191–197.

50. Cunningham D, Lang I, Marcuello E, *et al.* Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. *Lancet Oncol* 2013; 14: 1077–1085.

51. Garcia-Alfonso P, Munoz-Martin AJ, Alvarez-Suarez S, *et al.* Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. *Br J Cancer* 2010; 103: 1524–1528.

52. Garcia Alfonso P, Munoz Martin A, Alvarez-Suarez S, *et al.* Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. *BMC Cancer* 2015; 15: 327.

53. Maughan TS, Adams RA, Smith CG, *et al.* Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 2011; 377: 3617–3627.

54. Baker SD. Pharmacology of fluorinated pyrimidines: eniluracil. *Invest New Drugs* 2000; 18: 373–381.

55. Schilsky RL, and Kindler HL. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. *Expert Opin Investig Drugs* 2000; 9: 1635–1649.

56. Resolin MJ, Yan J, Weiss H, *et al.* Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. *Cancer Chemother Pharmacol* 2003; 52: 399–404.

57. Ochoa L, Hurwitz HI, Wilding G, *et al.* Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. *Ann Oncol* 2000; 11: 1313–1322.

58. Schilsky RL, Hohneker J, Ratain MJ, *et al.* Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. *J Clin Oncol* 1998; 16: 1450–1457.

59. Fazio VG, Caffarelli P, Del Chiaro M, *et al.* A pooled analysis of R,S-1-((tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes. *Cancer Res* 1983; 43: 4039–4044.

60. Casado E, Pfeiffer P, Feliu J, *et al.* UFT (tegafur-uracil) in rectal cancer. *Ann Oncol* 2008; 19: 1371–1378.

61. Buroker T, Padilla F, Groppe C, *et al.* Phase II evaluation of ftauruf in previously untreated colorectal cancer: a Southwest Oncology Group study. *Cancer* 1979; 44: 48–51.

62. Ansfield FJ, Kallas G and Singson J. Phase I-II studies of oral tegafur (ftorafur). *J Clin Oncol* 1983; 1: 107–110.

63. Brito RA, Medgyesy D, Zukowski TH, *et al.* Fluoropyrimidines: a critical evaluation. *Oncology* 1999; 57 (Suppl. 1): 2–8.

64. Douillard JY, Hoff PM, Skillings JR, *et al.* Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2002; 20: 3605–3616.

65. Carmichael J, Popiela T, Radstone D, *et al.* Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2002; 20: 3617–3627.

66. Bayoglu IV, Yildiz I, Varol U, *et al.* Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. *Contemp Oncol (Pozn)* 2015; 19: 385–390.

67. Bennouna J, Perrier H, Paillot B, *et al.* A phase II study of oral uracil/tegafur (UFT)
plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 2006; 94: 69–73.

73. Bennouna J, Saunders M and Douillard JY. The role of UFT in metastatic colorectal cancer. Oncology 2009; 76: 301–310.

74. Cubero DI, Cruz FM, Santi P, et al. Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol 2012; 4: 167–172.

75. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 2018; 23: 1–34.

76. Adis Insight. Drug profile. Tegafur/uracil. https://adisinsight.springer.com/drugs/800008791 (2019, accessed 27 May 2020).

77. Glasspool R and Cassidy J. Oral fluoropyrimidines in the adjuvant therapy of colon cancer. Curr Colorectal Cancer Rep 2006; 2: 137–141.

78. Miyamoto Y, Sakamoto Y, Yoshida N, et al. Efficacy of S-1 in colorectal cancer. Expert Opin Pharmacother 2014; 15: 1761–1770.

79. Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2013; 14: 1278–1286.

80. Cheng AL, Li J, Vaid AK, et al. Adaptation of international guidelines for metastatic colorectal cancer: an Asian consensus. Clin Colorectal Cancer 2014; 13: 145–155.

81. Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11: 853–860.

82. Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLOR): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 2018; 29: 624–631.

83. Taiho Pharma. News release: phase III clinical trial results of TS-1 on metastatic colorectal cancer published in digital version of Lancet Oncology. https://www.taiho.co.jp/en/release/2013/20131111.html (2013, accessed 16 September 2019).

84. European Medicines Agency (EMA). Teyusuno. EPAR summary for the public. https://www.ema.europa.eu/documents/overview/teysuno-epar-summary-public_en.pdf (2011, accessed 23 October 2018).

85. Wigle TJ, Tsvetkova EV, Welch SA, et al. DPYD and fluorouracil-based chemotherapy: mini review and case report. Pharmacutics 2019; 11: 199.

86. European Medicines Agency (EMA). EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing_en.pdf (2020, accessed 28 May 2020).

87. Fukushima M, Suzuki N, Emura T, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 2000; 59: 1227–1236.

88. Temmink OH, Emura T, De Bruin M, et al. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 2007; 98: 779–789.

89. Burness CB and Duggan ST. Trifluridine/Tipiracil: a review in metastatic colorectal cancer. Drugs 2016; 76: 1393–1402.

90. Chen J, Han M and Saif MW. TAS-102 an emerging oral fluoropyrimidine. Anticancer Res 2016; 36: 21–26.

91. Lenz HJ, Stintzing S and Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev 2015; 41: 777–783.

92. Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012; 13: 993–1001.

93. Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol 2018; 36: 350–358.
94. Lesniewski-Kmak K, Moiseenko V, Saunders MP, et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis. In: ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 20–23 June 2018. Lugano, Switzerland: ESMO.

95. Institut de Recherches Internationales Servier. An open-label, randomised, phase III study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidates for intensive therapy (SOLSTICE study) [EU Clinical Trials Registry number: 2017-004059-22]. https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004059-22/GB (2017, accessed 21 February 2019).

96. Kuboki Y, Nishina T, Shinozaki E, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol 2017; 18: 1172–1181.

97. Pfeiffer P, Yilmaz M, Möller S, et al. Randomized study evaluating trifluridine/tipiracil (TAS-102) versus trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC). J Clin Oncol 2019; 37: 637.

98. Kotaka M, Satake H, Oba K, et al. Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study). J Clin Oncol 2019; 37: 647.

99. Lee J and Chu E. Adherence, dosing, and managing toxicities with trifluridine/tipiracil (TAS-102). Clin Colorectal Cancer 2017; 16: 85–92.

100. Carter NJ. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. Drugs Aging 2014; 31: 67–78.

101. Bayer HealthCare Pharmaceuticals Inc. Stivarga. Prescribing information. http://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf (2012, accessed 23 October 2018).

102. Chionh F, Lau D, Yeung Y, et al. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 2017; 7: CD008398.

103. Pfeiffer P, Mortensen JP, Bjerregaard B, et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006; 42: 2738–2743.

104. Verso M and Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3655–3675.

105. Wakisaka S, Shimauchi M, Kaji Y, et al. Acute phenytoin intoxication associated with the antineoplastic agent UFT. Fukuoka Igaku Zasshi 1990; 81: 192–196.

106. Brickell K, Porter D and Thompson P. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports. Br J Cancer 2003; 89: 615–616.

107. Patel AK, Barghout V, Yenikomshian MA, et al. Real-world adherence in patients with metastatic colorectal cancer treated with trifluridine plus tipiracil or regorafenib. Oncologist 2020; 25: e75–e84.

108. Patel AK, Duh MS, Barghout V, et al. Real-world treatment patterns among patients with colorectal cancer treated with trifluridine/tipiracil and regorafenib. Clin Colorectal Cancer 2020; 17: e531–e539.

109. University of Southern California. A phase I/II study of regorafenib and pembrolizumab in metastatic colorectal cancer patients in 3rd and 4th line setting [ClinicalTrial.gov number: NCT03657641]. https://clinicaltrials.gov/ct2/show/NCT03657641 (2018, accessed 26 June 2020).

110. City of Hope Medical Center. A phase I clinical trial of regorafenib, nivolumab, and ipilimumab in advanced chemotherapy resistant metastatic MSS colorectal cancer [ClinicalTrials.gov number: NCT04362839]. https://clinicaltrials.gov/ct2/show/NCT04362839 (2020, accessed 26 June 2020).